Dramatic clinical response in the treatment of small cell glioblastoma multiforme. (11th January 2022)

• Record Type: Journal Article
• Authors: Zaman, Farzana Yasmin; McLean, Catriona; Ameratunga, Malaka
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 47:Number 6(2022)
• Page Start: 832
• Page End: 834
• Publication Date: 2022-01-11
• Subjects: chemoradiotherapy -- small cell glioblastoma multiforme -- temozolomide; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.13608
• Languages: English
• ISSNs: 0269-4727

Abstract

Abstract: What is known and objective: Small cell glioblastoma (scGBM) is a rare subtype of primary glioblastoma, which typically behave more aggressively compared with classical glioblastoma (GBMs). They are generally associated with poor responses to treatment, and optimal treatment is not known. Case summary: We present the case of a 51‐year‐old woman with scGBM with O 6 ‐methylguanine DNA methyltransferase (MGMT) promoter methylation, demonstrating an unexpected dramatic clinical response to chemoradiotherapy. What is new and conclusion: This case highlights that treatment with temozolomide‐based chemoradiotherapy is justified in patients with scGBM, despite their poor prognosis. MGMT methylation may be associated with clinical responses.